Nautilus Biotechnology (NAUT) Cash from Operations (2020 - 2026)

Nautilus Biotechnology has disclosed Cash from Operations across 7 years of filings, most recently posting 13100000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 13100000.0, up 6.01% year-over-year; the trailing twelve-month figure through Mar 2026 was 49859000.0 (up 12.24% YoY), and the FY2025 annual result was 50696000.0, up 14.29% from the prior year.
• Cash from Operations came in at 13100000.0 for Q1 2026 at Nautilus Biotechnology, down from 12375000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 9565000.0 in Q3 2022 to a low of 16266000.0 in Q1 2024.
• The 5-year median for Cash from Operations is 13113000.0 (2024), against an average of 12968117.65.
• Peak annual rise in Cash from Operations reached 32.53% in 2022, while the deepest fall reached 97.27% in 2022.
• Nautilus Biotechnology's Cash from Operations stood at 10377000.0 in 2022, then slumped by 33.95% to 13900000.0 in 2023, then retreated by 2.94% to 14309000.0 in 2024, then advanced by 13.52% to 12375000.0 in 2025, then fell by 5.86% to 13100000.0 in 2026.
• The last three Cash from Operations figures came in at 13100000.0 (Q1 2026), 12375000.0 (Q4 2025), and 11034000.0 (Q3 2025), per Business Quant data.